Guangzhou Topwork Chemical Co., Ltd. | China | Inquire | ||
---|---|---|---|---|
![]() |
+86 (20) 8731-7062 +86 13544492387 | |||
![]() |
sales@topworkchem.com topwork2004@hotmail.com | |||
![]() |
Skype Chat | |||
![]() |
QQ chat | |||
![]() |
WeChat: 13544492387 | |||
![]() |
WhatsApp: 13544492387 | |||
Chemical manufacturer since 2004 | ||||
chemBlink standard supplier since 2006 | ||||
Shanghai SPE Chemicals Co., Ltd. | China | Inquire | ||
---|---|---|---|---|
![]() |
+86 (21) 5138-6314 | |||
![]() |
info@spechemicals.com | |||
Chemical manufacturer | ||||
chemBlink standard supplier since 2006 | ||||
Beijing Huafeng United Technology Co., Ltd. | China | Inquire | ||
---|---|---|---|---|
![]() |
+86 (10) 5786-2036 57862181 65405760 +86 13366977697 | |||
![]() |
huafenginfo@126.com | |||
![]() |
QQ chat | |||
Chemical manufacturer since 2005 | ||||
chemBlink standard supplier since 2007 | ||||
Zhangjiagang Sunrise Fine Chemical Co., Ltd. | China | Inquire | ||
---|---|---|---|---|
![]() |
+86 (574) 8797-0832 | |||
![]() |
info@sfcc.com.cn | |||
Chemical manufacturer since 2000 | ||||
chemBlink standard supplier since 2008 | ||||
Simagchem Corporation | China | Inquire | ||
---|---|---|---|---|
![]() |
+86 13806087780 | |||
![]() |
sale@simagchem.com | |||
Chemical manufacturer since 2002 | ||||
chemBlink standard supplier since 2008 | ||||
Discovery Fine Chemicals Ltd. | UK | Inquire | ||
---|---|---|---|---|
![]() |
+44 (1202) 874-517 | |||
![]() |
pjc@discofinechem.com | |||
Chemical manufacturer | ||||
chemBlink standard supplier since 2009 | ||||
Taizhou Crene Biotechnology Co., Ltd. | China | Inquire | ||
---|---|---|---|---|
![]() |
+86 (576) 8881-3233 8820-5808 +86 13396860566 | |||
![]() |
order@pharm-intermediates.com | |||
![]() |
QQ chat | |||
Chemical manufacturer since 2011 | ||||
chemBlink standard supplier since 2009 | ||||
Xingcheng Chempharm Co., Ltd. | China | Inquire | ||
---|---|---|---|---|
![]() |
+86 (576) 8855-1200 8852-5005 8888-0039 | |||
![]() |
sales@xingchengchem.com | |||
Chemical manufacturer | ||||
chemBlink standard supplier since 2009 | ||||
Classification | API >> Antineoplastic agents >> Antibiotic antineoplastic agents |
---|---|
Name | Doxorubicin hydrochloride |
Synonyms | (8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxynaphthacene-5,12-dione hydrochloride |
Molecular Structure | ![]() |
Molecular Formula | C27H29NO11.HCl |
Molecular Weight | 579.99 |
CAS Registry Number | 25316-40-9 |
EC Number | 246-818-3 |
SMILES | C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl |
Solubility | 50 mM (H2O), 50 mM (DMSO) (Expl.) |
---|---|
Melting point | 216 ºC (decomp.) (Expl.) |
Hazard Symbols |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hazard Statements | H302-H315-H319-H340-H350-H360 Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Precautionary Statements | P203-P264-P264+P265-P270-P280-P301+P317-P302+P352-P305+P351+P338-P318-P321-P330-P332+P317-P337+P317-P362+P364-P405-P501 Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Hazard Classification | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SDS | Available | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Doxorubicin hydrochloride is a widely used chemotherapeutic agent that belongs to the anthracycline class of drugs. It is primarily used in the treatment of various cancers, including breast cancer, ovarian cancer, lung cancer, and leukemia. Doxorubicin works by intercalating into DNA strands, disrupting DNA replication and transcription, which ultimately leads to cell death. It also generates free radicals that cause further cellular damage. Due to its potent anticancer properties, doxorubicin has become one of the cornerstone drugs in chemotherapy regimens for a variety of malignancies. The discovery of doxorubicin dates back to the 1950s, when it was isolated from *Streptomyces peucetius*, a bacterium found in soil. Initially, researchers were investigating microbial sources of potential anticancer agents, and the discovery of doxorubicin marked a significant breakthrough. The drug was first introduced to clinical use in the early 1970s, following extensive preclinical and clinical trials that demonstrated its efficacy against a wide range of cancers. It was marketed under the trade name Adriamycin and quickly gained recognition as an essential part of cancer chemotherapy. Doxorubicin hydrochloride has been used in the treatment of both solid tumors and hematologic cancers. In breast cancer, for example, it is often used as part of combination chemotherapy regimens like AC (doxorubicin and cyclophosphamide) or FAC (fluorouracil, doxorubicin, and cyclophosphamide). It is also used to treat various leukemias, lymphomas, and sarcomas. The drug is typically administered intravenously, although it may also be given by other routes depending on the type of cancer being treated. One of the challenges in the use of doxorubicin is its potential for causing significant side effects. These include cardiotoxicity, which can lead to long-term heart damage, as well as nausea, vomiting, hair loss, and myelosuppression, which affects the bone marrow’s ability to produce blood cells. The cardiotoxicity associated with doxorubicin is dose-dependent, and the cumulative dose over time can increase the risk of heart failure. As a result, patients receiving doxorubicin are closely monitored for signs of heart damage, and the drug's dosage is adjusted to minimize these risks. To mitigate cardiotoxicity, doxorubicin is often used in combination with other drugs that protect the heart, such as dexrazoxane, which reduces the drug’s harmful effects on heart tissue. Doxorubicin has also inspired the development of liposomal formulations, which aim to reduce its toxicity while maintaining its efficacy. Liposomal doxorubicin, such as the product Doxil, is encapsulated in lipid-based nanoparticles, which allow for targeted drug delivery to cancer cells. This formulation helps to reduce the incidence of side effects, such as hair loss and cardiotoxicity, by limiting the exposure of healthy tissues to the drug. Liposomal doxorubicin is particularly useful in the treatment of ovarian cancer and Kaposi’s sarcoma. Despite its side effects, doxorubicin remains an essential and highly effective chemotherapeutic agent. Researchers continue to explore ways to improve its delivery, reduce its toxicities, and enhance its anticancer activity. The use of doxorubicin in combination with other drugs, as well as the development of new formulations and drug delivery systems, holds promise for improving cancer treatment outcomes in the future. In conclusion, doxorubicin hydrochloride is a crucial drug in the treatment of various cancers. Its discovery from microbial sources revolutionized cancer chemotherapy, and its potent anticancer effects have made it a standard treatment option for many malignancies. While its use is associated with significant side effects, including cardiotoxicity, ongoing research continues to enhance its clinical application, making it a cornerstone in the fight against cancer. References Chabner, B. A., & Roberts, T. G. (2005). Timeline: Chemotherapy and the war on cancer. Nature Reviews Cancer, 5(1), 65-72. Vahid, F., & Thompson, C. (2007). Doxorubicin and its clinical application in chemotherapy. Journal of Clinical Oncology, 25(16), 2895-2904. Schwartz, G. N., & Fadul, C. (2011). Doxorubicin: The role in cancer treatment. Cancer Treatment Reviews, 37(1), 51-59. |
Market Analysis Reports |
List of Reports Available for Doxorubicin hydrochloride |